SCONE Study Studies on Complement regulation in atypical hemolytic uremic syndrome following hemodialysis, plasmapheresis and treatment with Eculizumab

Completed

• Conditions: hemolytic uremic syndrome; HUS; 10038360; 10027665; 10038430

• Registration Number: NL-OMON37013
• Lead Sponsor: niversitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

- age more than 12 years
- diagnosis of atypical HUS
- treatment either with hemodialysis, plasmapheresis or eculizumab
- after giving written informed consent

Exclusion Criteria

no informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Tests: -Levels of complement factors: C3, C3b, Complement Factor H quantitative<br /><br>(ELISA), Complement factor I (ELISA), CFB, sC5-9 membrane attack complex,<br /><br>Presence of C3b on erythrocytes, Functional assay: Complement Factor H, MCP<br /><br>expression on leucocytes (flow cytometer), tests of coagulation and endothelial<br /><br>function, Micro endothelial particles, circulating DNA (nucleosomen), FSAP<br /><br>(factor VII-activating protease.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p> not applicable</p><br>